The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

The study aims to evaluate the safety and clinical effect of daily oral treatment with laquinimod capsules (0.5mg /day and 1mg /day) in active lupus arthritis patients. Laquinimod is a novel immunomodulating drug which is currently in advanced stages of development by Teva Pharmaceuticals Ltd. For Multiple Sclerosis.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:

18 Years to 75 Years (Adult, Senior)

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria:

Subjects diagnosed with SLE.

Subjects with active lupus arthritis as evident by

At least 4 tender and 4 swollen joints

Active synovitis ≥ 1 joint with some loss of functional range of movement

Exclusion Criteria:

Subjects with severe renal impairment or dialysis

Severe, unstable and/or progressive CNS lupus

Subjects with a clinically significant or unstable medical or surgical condition

Women who are pregnant or nursing or who intend to be during the study period.

Women of child-bearing potential who do not practice an acceptable method of birth control